Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.49 |
| ▸ | HTR2A | P28223 | 11/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24144473 | 0.86 | HTR7 (0.52) | HTR2CHTR2AHTR7CYP1A2CYP3A4 | |
| SCHEMBL20353866 | 0.81 | HTR7 (0.44) | HTR2CHTR2AHTR7MCL1EPHX2 | |
| SCHEMBL25154150 | 0.78 | HTR2C (0.76) | HTR2CHTR2AHTR7CYP1A2CYP3A4 | |
| SCHEMBL15712674 | 0.77 | HTR2C (0.55) | HTR2CHTR2AHTR7CYP1A2CYP3A4 | |
| SCHEMBL26673242 | 0.77 | HTR2C (0.77) | HTR2CHTR2AHTR7CYP1A2CYP3A4 | |
| SCHEMBL24144837 | 0.77 | HTR2C (0.58) | HTR2CHTR2AHTR7CYP1A2CYP3A4 | |
| SCHEMBL24142902 | 0.77 | HTR7 (0.63) | HTR2CHTR2AHTR7 | |
| SCHEMBL26674331 | 0.77 | HTR7 (0.53) | HTR2CHTR2AHTR7CYP1A2CYP3A4 | |
| SCHEMBL12277160 | 0.75 | KMT2A (0.55) | MCL1EPHX2NR1H4 | |
| SCHEMBL25037435 | 0.75 | MCL1 (0.53) | HTR2CHTR2AHTR7MCL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | HTR2C 3626/4885HTR2A 3630/4885HTR7 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.